Jeffrey D. Alexis, M.D.

Jeffrey D. Alexis, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 679
Rochester, NY 14642

Office: (585) 276-9795
Fax: (585) 276-9830
Lab: (585) 276-9845
Administrative: (585) 276-9800

Lab Information

Visit Lab Website »

Professional Bio

Dr. Alexis earned his M.D. from Harvard University in 1992. He was an intern and resident from 1992- 1995 at the Massachusetts General Hospital and completed his cardiology fellowship in 1998 at the Mount Sinai School of Medicine. He served on the faculty of the Mount Sinai School of Medicine (1998-2003) and joined the faculty of the University of Rochester in 2003 as an Assistant Professor of Medicine. He is Board Certified in Internal Medicine and Cardiovascular Disease. Dr. Alexis is a member of the heart failure/transplant section and his research focuses on left ventricular assist devices.

Research Bio

Research in Dr. Alexis' lab focuses on signaling pathways that regulate intimal proliferation. Intimal proliferation occurs in several pathologic states including transplant arteriopathy and restenosis following angioplasty. Smooth muscle cell inflammation and proliferation are important aspects of this pathology. Our research focuses on the role of breakpoint cluster region (Bcr) in the development of intimal proliferation. Bcr was first identified for its role as part of the Philadelphia chromosome in chronic myelogenous leukemia. Bcr is also a serine/threonine kinase. We have demonstrated that Bcr plays a role in vascular wall intimal proliferation.

We have shown that Bcr regulates both inflammation and proliferation in vascular smooth muscle cells (VSMC). Specifically, we have shown that dominant negative Bcr reversed Angiotensin II-mediated inhibition of the transcription factor PPAR gamma. We have found that Angiotensin II increases Bcr expression and kinase activation. We have shown that Bcr is present in the nucleus of smooth muscle cells and phosphorylates PPAR gamma. We have also shown that Bcr inhibits PPAR gamma transcriptional activation. This inhibition is via phosphorylation of PPAR gamma at S82, the site at which ERK 1/2 phosphorylates PPAR gamma (also leading to inhibition of PPAR gamma). Our data also demonstrate that Bcr enhances NF-kB transcriptional activity at least in part via inhibition of PPAR gamma. Intimal proliferation in low-flow carotid arteries was reduced in Bcr knockout mice compared with controls, demonstrating a critical role of Bcr on VSMC proliferation in vivo. Our current work focuses on Bcr signaling independent of PPAR gamma. We have identified the splicing factor UAP56 as another Bcr kinase substrate and we are now investigating the role of UAP56 in cellular proliferation.

Awards & Honors (Local)

Teaching Award: Institute for Medical Education Mount Sinai School of Medicine 2003
Robert Wood Johnson Minority Medical Faculty Development Grant 2000
John C. Sable Memorial Heart Fund, Inc. Award 1998
Selection to Aesculapian Club of Harvard Medical School 1992
Harvard Medical School-Hewlett-Packard Top Medical Graduate Award 1992
Harvard Medical School Summer Research Scholarship 1989

Recent Journal Articles

Showing the 5 most recent journal articles. 7 available »

Alexis, J.D.; Wang, N.; Che, W.; Lerner-Marmarosh, N.; Sahni, A.; Korshunov, V.A.; Zou, Y.; Ding, B.; Yan, C.; Berk, B.C.; Abe, J. "Bcr kinase activation by Angiotensin II inhibits PPARg transcriptional activity in vascular smooth muscle cells." Circulation Research. 2009; 104: 69-78.
Alexis,J.D.; Pyo,R.T.; Chereshnev,I.; Katz J.; Rollins,B.J.; Charo I.F.; Taubman,M.B. "Inhibition of MCP-1/CCR2 signaling does not inhibit intimal proliferation in a mouse aortic transplant model." Journal of Vascular Research. 2008; 45: 538-546.
Strain,J. J.; Karim,A.; Caliendo,G.; Alexis,J. D.; Lowe,R. S.,3rd; Fuster,V. "Cardiac drug-psychotropic drug update". General Hospital Psychiatry. 2002; 24: 283-289.
Strain,J. J.; Caliendo,G.; Alexis,J. D.; Lowe,R. S.,3rd; Karim,A.; Loigman,M. "Cardiac drug and psychotropic drug interactions: significance and recommendations." General Hospital Psychiatry. 1999; 21: 408-429.
*Freudenberger,R.; *Alexis,J.; Gass,A.; Fuster,V.; Badimon,J. "Antithrombotic effect of FK 506 versus cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy." The Journal of Heart and Lung Transplantation: the official publication of the International Society for Heart Transplantation. 1999; 18: 1228-31. *Contributed equally to this work.

Current Appointments

Associate Professor - Department of Medicine, Cardiology (SMD) - Primary


Internal Medicine - American Board of Internal Medicine
Advanced Heart Failure and Transplant Cardiology - American Board of Internal Medicine
Cardiovascular Disease - American Board of Internal Medicine


MD | Medicine | Harvard Medical School1992
BA | Mathematics | Harvard College (Cum laude)1988

Post-Doctoral Training & Residency

Fellowship in Cardiology at Mount Sinai Hospital Cardiovascular Institute07/01/1995 - 06/30/1998
Residency in Internal Medicine at Massachusetts General Hospital07/01/1993 - 06/30/1995
Internship in Internal Medicine at Massachusetts General Hospital07/01/1992 - 06/30/1993